{"entity":{"id":"andrew-wardley","kind":"person","name":"Andrew Wardley","aka":[],"tldr":"Andrew Wardley is a breast oncologist involved in the PERSEPHONE trial of shorter trastuzumab.","summary":"Andrew Wardley is a consultant medical oncologist at The Christie NHS Foundation Trust and Honorary Professor at the University of Manchester. He specialises in breast cancer, HER2-positive disease and adjuvant trials. He contributed to PERSEPHONE, the trial that compared six months with twelve months of adjuvant trastuzumab. His papers include the monarcHER phase 2 trial of abemaciclib plus trastuzumab with or without fulvestrant in hormone receptor-positive, HER2-positive advanced breast cancer, the PERUSE study of first-line pertuzumab with trastuzumab and a taxane, and a study of enzalutamide with trastuzumab in HER2-positive, androgen receptor-positive disease. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wardley%20A%5BAuthor%5D%20breast%20trastuzumab"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab"],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":["persephone"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["breast-cancer-research-and-treatment"],"dependsOn":[],"notes":[],"role":"Consultant Medical Oncologist, The Christie; Honorary Professor, University of Manchester","institutionId":"the-christie","specialisms":["Breast cancer","HER2-positive disease","Adjuvant trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wardley%20A%5BAuthor%5D%20breast%20trastuzumab"}],"papers":[{"title":"The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer","journal":"Breast Cancer Research and Treatment","year":2021,"doi":"10.1007/s10549-021-06109-7"},{"title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(20)30112-1"},{"title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz061"},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"}],"orcid":"0000-0002-9639-0888"},"route":"/people/andrew-wardley/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"institution":[{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/"}],"trial":[{"id":"persephone","kind":"trial","name":"PERSEPHONE","route":"/trials/persephone/"}],"journal":[{"id":"breast-cancer-research-and-treatment","kind":"journal","name":"Breast cancer research and treatment","route":"/journals/breast-cancer-research-and-treatment/"}],"paper":[{"id":"paper-monarche-jco-2020","kind":"paper","name":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","route":"/key-papers/paper-monarche-jco-2020/"}]}}